M&A

Merck to Acquire Animal Tracking and Monitoring Company
Merck to Acquire Animal Tracking and Monitoring Company
CP Wire
Merck Animal Health
Merck
animal health
M&A
Antelliq
Flag link:
Astellas gains three cancer drugs with $405m Potenza buy
Astellas gains three cancer drugs with $405m Potenza buy
Pharmaforum
Astellas
Potenza Therapeutics
M&A
cancer immunotherapy
Flag link:
To Cover Debts, Synergy Inks $200M Bankruptcy Sale to Bausch Health
To Cover Debts, Synergy Inks $200M Bankruptcy Sale to Bausch Health
Xconomy
Synergy Pharmaceuticals
bankruptcy
Bausch Health
M&A
Flag link:
Akorn's CEO bows out after failing last-ditch bid to save Fresenius merger
Akorn's CEO bows out after failing last-ditch bid to save Fresenius merger
Fierce Pharma
Akorn
Fresenius
M&A
Flag link:
Are Medtech Companies Still Interested in M&A?
Are Medtech Companies Still Interested in M&A?
Medical Devices and Diagnostics Industry
devices
M&A
Flag link:
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
M&A
Biomarin
Vertex Pharmaceuticals
Incyte
Alnylam
Alexion
Flag link:
Could These Be the Next 2 Biotech Buyouts?
Could These Be the Next 2 Biotech Buyouts?
Motley Fool
biotech
M&A
Agios Pharmaceuticals
Clovis Oncology
Flag link:
Millendo, OvaScience merge, raise $50M
Millendo, OvaScience merge, raise $50M
BioCentury
Millendo Therapeutics
OvaScience
M&A
Flag link:
Akorn fights to salvage Fresenius deal in appeal to Delaware Supreme Court
Akorn fights to salvage Fresenius deal in appeal to Delaware Supreme Court
Fierce Pharma
Akorn
Fresenius
M&A
Flag link:
Mereo BioPharma, OncoMed agree to merge
Mereo BioPharma, OncoMed agree to merge
Pharmaceutical Business Review
M&A
Mereo BioPharma
OncoMed
Flag link:
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
Endpoints
Takeda
Shire
M&A
Flag link:
Should You Be Worried About the Return of Big Pharma Deals?
Should You Be Worried About the Return of Big Pharma Deals?
Motley Fool
GSK
Tesaro
M&A
Big Pharma
JNJ
Argenx
Flag link:
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca
Xconomy
GSK
M&A
Tesaro
PARP inhibitors
Zejula
AstraZeneca
Flag link:
Crown Laboratories buys select OTC consumer healthcare brands from GSK
Crown Laboratories buys select OTC consumer healthcare brands from GSK
Pharmaceutical Business Review
Crown Laboratories
GSK
OTC
M&A
Flag link:
Judge threatened to delay or even spike $70m CVS-Aetna merger
Judge threatened to delay or even spike $70m CVS-Aetna merger
Mass Device
Aetna
CVS Health
M&A
Flag link:
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Forbes
Shire
Takeda
R&D
M&A
Flag link:
Takeda ready to dismiss assets for a total $10bn
Takeda ready to dismiss assets for a total $10bn
GoinPharma
Takeda
Shire
M&A
Flag link:
Gilead can now attempt at takeover of Galapagos
Gilead can now attempt at takeover of Galapagos
GoinPharma
Gilead Sciences
Galapagos
M&A
Flag link:
M&A trends in 2019: Will the biotech bubble burst?
M&A trends in 2019: Will the biotech bubble burst?
Biopharma Dive
M&A
Flag link:
Takeda could rack up $10B in selloffs after controversial Shire buyout: report
Takeda could rack up $10B in selloffs after controversial Shire buyout: report
Fierce Pharma
Takeda
Shire
M&A
shareholders
Flag link:

Pages